Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Immunocore HoldingsIMCR | Open-market sale | 02/18 | 02/19 | 11,474 sh | $32.35 | $371,183.9 | −48.2% | |
John GollSVP, Finance & Cao | Immunocore HoldingsIMCR | Open-market sale | 02/18 | 02/19 | 698 sh | $32.35 | $22,580.3 | −51.7% |
David M. BermanHead of R&d | Immunocore HoldingsIMCR | Open-market sale | 02/18 | 02/19 | 5,965 sh | $32.35 | $192,967.75 | −50.4% |
Tina Amber St LegerChief Hr Officer | Immunocore HoldingsIMCR | Open-market sale | 02/18 | 02/19 | 1,000 sh | $32.35 | $32,350 | −47.2% |
Immunocore HoldingsIMCR | Open-market sale10b5-1 plan | 25/12/04–25/12/05 | 25/12/08 | 31,913 sh2 trades | $40.26avg. | $1,284,748.74 | −100.0% | |
Immunocore HoldingsIMCR | Open-market sale10b5-1 plan | 25/11/26–25/11/28 | 25/12/01 | 74,925 sh2 trades | $40.12avg. | $3,005,825.37 | −100.0% | |
Immunocore HoldingsIMCR | Open-market sale10b5-1 plan | 25/11/24–25/11/25 | 25/11/26 | 18,120 sh2 trades | $40.03avg. | $725,340.6 | −100.0% | |
David M. BermanHead of R&d | Immunocore HoldingsIMCR | Open-market sale10b5-1 plan | 25/09/30 | 25/10/02 | 61,849 sh | $35.23 | $2,178,940.27 | −100.0% |
Immunocore HoldingsIMCR | Open-market sale10b5-1 plan | 25/09/12–25/09/15 | 25/09/16 | 22,732 sh3 trades | $35.66avg. | $810,701.16 | −100.0% | |
Immunocore HoldingsIMCR | Open-market sale10b5-1 plan | 25/09/10–25/09/11 | 25/09/12 | 50,419 sh3 trades | $36.20avg. | $1,824,967.24 | −100.0% | |
Immunocore HoldingsIMCR | Open-market buy | 25/03/17 | 25/03/19 | 807,338 sh4 trades | $29.72avg. | $23,992,063.28 | +60.4% | |
Immunocore HoldingsIMCR | Open-market buy | 25/03/17 | 25/03/19 | 807,338 sh4 trades | $29.72avg. | $23,992,063.28 | +60.4% | |
Immunocore HoldingsIMCR | Open-market buy | 25/03/17 | 25/03/19 | 807,338 sh4 trades | $29.72avg. | $23,992,063.28 | +60.4% | |
Immunocore HoldingsIMCR | Open-market buy | 25/03/17 | 25/03/19 | 807,338 sh4 trades | $29.72avg. | $23,992,063.28 | +60.4% | |
Immunocore HoldingsIMCR | Open-market buy | 25/03/17 | 25/03/19 | 807,338 sh4 trades | $29.72avg. | $23,992,063.28 | +60.4% | |
Immunocore HoldingsIMCR | Open-market buy | 25/03/17 | 25/03/19 | 807,338 sh4 trades | $29.72avg. | $23,992,063.28 | +60.4% | |
Tina Amber St LegerChief Hr Officer | Immunocore HoldingsIMCR | Open-market sale10b5-1 plan | 24/04/01 | 24/04/03 | 4,375 sh | $64.06 | $280,262.5 | −100.0% |
Immunocore HoldingsIMCR | Open-market sale10b5-1 plan | 24/02/28 | 24/03/01 | 36,509 sh4 trades | $68.59avg. | $2,504,158.49 | −100.0% | |
Immunocore HoldingsIMCR | Open-market sale10b5-1 plan | 24/02/26–24/02/27 | 24/02/28 | 83,491 sh6 trades | $70.79avg. | $5,910,317.77 | −100.0% | |
Immunocore HoldingsIMCR | Open-market sale10b5-1 plan | 24/01/03 | 24/01/05 | 4,375 sh2 trades | $69.89avg. | $305,781.02 | −100.0% |